Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1150 ARTÍCULOS , VIENDO DEL 856 AL 870

Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease

Yao J, Brinton RD.

Adv Pharmacol. 2012;64:327-71. doi: 10.1016/B978-0-12-394816-8.00010-6.

[Biological markers in the diagnosis of dementia and Alzheimer's disease]

Meiner Z, Rosenmann H.

Harefuah. 2012 May;151(5):289-93, 318.

The imbalance of vascular molecules in Alzheimer's disease

Bell RD.

J Alzheimers Dis. 2012;32(3):699-709. doi: 10.3233/JAD-2012-121060.

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2012 Aug 28;79(9):897-905. doi: 10.1212/WNL.0b013e318266fa70. Epub 2012 Aug 1.

Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease

Grela A, Turek A, Piekoszewski W.

Clin Chem Lab Med. 2012 Feb 11;50(8):1297-304. doi: 10.1515/cclm-2011-0550.

Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study

Handels RL, Aalten P, Wolfs CA, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FR.

BMC Neurol. 2012 Aug 10;12:72. doi: 10.1186/1471-2377-12-72.

Predictive biomarkers for Alzheimer's disease using state-of-the-art brain imaging techniques

Mandal PK.

J Alzheimers Dis. 2012;31 Suppl 3:S1-3. doi: 10.3233/JAD-2012-120731.

Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment

Visser PJ, Wolf H, Frisoni G, Gertz HJ.

Biomark Med. 2012 Aug;6(4):365-8. doi: 10.2217/bmm.12.58.

Analytical aspects of molecular Alzheimer's disease biomarkers

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44.

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.

Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers

Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39.

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease

Herholz K.

Biomark Med. 2012 Aug;6(4):431-9. doi: 10.2217/bmm.12.51.

Plasma biomarkers for Alzheimer's disease: much needed but tough to find

Bazenet C, Lovestone S.

Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48.

Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease

Fagan AM, Perrin RJ.

Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias